Natural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X‐Linked Adrenoleukodystrophy
Open Access
- 19 March 2026
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (2) , e70176
Abstract
X‐linked adrenoleukodystrophy (X‐ALD) is a rare monogenic disorder characterized by marked variability in clinical presentation, age at onset, and disease progression. A deeper understanding of its natural history and the relationship between biochemical markers and clinical phenotypes is essential for improving disease monitoring, patient counseling, and optimizing clinical trial design. In particular, the predictive value of very long‐chain fatty acids (VLCFA) for clinical phenotypes has recently garnered increased attention. In this longitudinal, mixed prospective/retrospective, single‐center study, we analyzed clinical and biochemical data from 364 patients with X‐ALD (255 males). Parameters included clinical scores (EDSS, AACS), age at symptom onset, and disease manifestations, which were correlated with individual VLCFA levels. Patients with adrenal insufficiency (AI) exhibited significantly elevated VLCFA concentrations. Higher C26:0 levels were associated with faster progression (measured by EDSS); however, effect sizes were small and inter‐individual variability considerable. Although initial symptom severity was comparable between sexes, males presented earlier and progressed faster. Among patients seen in early clinical stages (EDSS ≤ 4.5), disease progression rates were higher (males: 0.34 ± 0.77; females: 0.11 ± 0.11) than in those presenting at more advanced stages (EDSS > 4.5; males: 0.23 ± 0.33; females: 0.09 ± 0.10). We provide comprehensive data on the prevalence of disease manifestations and the natural course of X‐ALD in a large adult cohort. The observed association between elevated VLCFA levels and adrenal insufficiency should be considered in future clinical monitoring and trial design. However, due to the small effect sizes and variability, VLCFA levels offer limited prognostic utility for individual patients.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SPP2395)
- Sächsische Aufbaubank (100601615)
- Bundesministerium für Gesundheit (ZMVI1 ‐2520DAT94B)
This publication has 34 references indexed in Scilit:
- Progression of Spinal Cord Disease in Adult Men With AdrenoleukodystrophyJournal of Inherited Metabolic Disease, 2025
- International validation of meaningfulness of postural sway and gait to assess myeloneuropathy in adults with adrenoleukodystrophyJournal of Inherited Metabolic Disease, 2024
- Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple SclerosisJAMA Neurology, 2023
- Self‐reported quality of life in symptomatic and asymptomatic women with X‐linked adrenoleukodystrophyBrain and Behavior, 2023
- Peroxisomes attenuate cytotoxicity of very long-chain fatty acidsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2022
- Sensorimotor outcomes in adrenomyeloneuropathy show significant disease progressionJournal of Inherited Metabolic Disease, 2021
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Microglia damage precedes major myelin breakdown in X‐linked adrenoleukodystrophy and metachromatic leukodystrophyGlia, 2019
- The role of ELOVL1 in very long‐chain fatty acid homeostasis and X‐linked adrenoleukodystrophyEMBO Molecular Medicine, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009